Natural Alternatives International Inc balance sheet
At the end of fiscal 2026, Natural Alternatives International Inc had total assets of $126m, total liabilities of $76.5m and shareholders' equity of $50.0m. It held $7.4m in cash against $18.0m of debt.
Balance sheet
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15 | 14 | 17 | 20 | 19 | 20 | 28 | 24 | 25 | 30 | 32 | 22 | 14 | 12 | 12 | 7 |
| Receivables | 3 | 9 | 7 | 7 | 10 | 13 | 8 | 15 | 16 | 17 | 18 | 17 | 7 | 17 | 15 | 21 |
| Inventory | 6 | 8 | 10 | 13 | 13 | 21 | 14 | 24 | 26 | 28 | 27 | 32 | 30 | 24 | 25 | 31 |
| Total current assets | 28 | 35 | 35 | 41 | 44 | 56 | 52 | 65 | 71 | 79 | 80 | 77 | 57 | 62 | 59 | 65 |
| Total assets | 41 | 47 | 47 | 52 | 54 | 74 | 73 | 85 | 114 | 120 | 120 | 146 | 134 | 162 | 152 | 126 |
| Accounts payable | 2 | 4 | 4 | 6 | 5 | 13 | 5 | 10 | 9 | 13 | 12 | 16 | 8 | 13 | 15 | 18 |
| Deferred revenue (current) | — | — | — | — | — | — | — | — | — | 0 | 2 | 0 | 0 | 0 | 1 | 1 |
| Total current liabilities | 5 | 7 | 6 | 10 | 9 | 19 | 10 | 14 | 14 | 28 | 22 | 24 | 16 | 23 | 29 | 38 |
| Long-term debt | — | — | — | — | — | 0 | 0 | 0 | 0 | — | 0 | 9 | 9 | 9 | 9 | 10 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 10 | 10 | 12 | 11 | 18 |
| Total liabilities | 6 | 7 | 6 | 10 | 10 | 20 | 11 | 17 | 17 | 49 | 40 | 57 | 45 | 80 | 84 | 76 |
| Shareholders' equity | 35 | 40 | 40 | 42 | 44 | 54 | 61 | 68 | 76 | 71 | 80 | 89 | 89 | 83 | 68 | 50 |
| Non-controlling interests and other (assets − liabilities − equity) | — | — | — | — | — | — | — | — | 21 | — | — | — | — | — | — | — |
| Shares outstanding | 7m | 7m | 7m | 7m | 7m | 7m | 7m | 8m | 7m | 7m | 6m | 6m | 6m | 6m | 6m | 6m |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 18 | 17 | 12 | 15 | 19 | 18 | 21 | 21 |
| Inventory | 26 | 23 | 27 | 25 | 31 | 33 | 30 | 31 |
| Total current assets | 62 | 59 | 59 | 59 | 65 | 62 | 64 | 65 |
| Total assets | 161 | 156 | 155 | 152 | 157 | 153 | 155 | 126 |
| Accounts payable | 10 | 9 | 13 | 15 | 20 | 17 | 18 | 18 |
| Deferred revenue (current) | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Total current liabilities | 24 | 22 | 23 | 29 | 34 | 33 | 39 | 38 |
| Long-term debt | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 10 |
| Total debt | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 10 |
| Total liabilities | 81 | 77 | 78 | 84 | 88 | 86 | 92 | 76 |
| Shareholders' equity | 80 | 79 | 77 | 68 | 69 | 67 | 63 | 50 |
| Shares outstanding | 6m | 6m | 6m | 6m | 6m | 6m | 6m | 6m |
Compare with peers
- Zevra Therapeutics, Inc. balance sheet
- Heron Therapeutics, Inc. balance sheet
- Niagen Bioscience, Inc. balance sheet
- Amarin Corp plc\uk balance sheet
- Cronos Group Inc. balance sheet
Head to head: NAII vs ZVRAHRTX vs NAIINAGE vs NAII
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies